Published online before print July 31, 2008

This Article Full Text (Rapid PDF) All Versions of this Article: jmoldx.2008.080015v1 jmoldx.2008.080015v2 10/5/435    most recent Purchase Article View Shopping Cart Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Google Scholar Articles by Pancrazzi, A. Articles by Vannucchi, A. M. PubMed PubMed Citation Articles by Pancrazzi, A. Articles by Vannucchi, A. M.

Copyright © 2008 American Society for Investigative Pathology
Journal of Molecular Diagnostics, doi:10.2353/jmoldx.2008.080015

Accepted for publication April 17, 2008.

Article

A Sensitive Detection Method for MPLW515L or MPLW515K Mutation in Chronic Myeloproliferative Disorders with Locked Nucleic Acid-Modified Probes and Real-Time Polymerase Chain Reaction

Alessandro Pancrazzi^*, Paola Guglielmelli^*, Vanessa Ponziani^*, Gaetano Bergamaschi, Alberto Bosi^*, Giovanni Barosi, and Alessandro M. Vannucchi^*@

From UF di Ematologia,* Dipartimento di Area Critica Medico-Chirurgica, University of Florence, Florence; Istituto Toscano Tumori, Florence; and Unit of Internal Medicine, Laboratory of Clinical Epidemiology, Transplant Research Area and Laboratory of Biotechnology, Istituto di Ricerca e Cura a Carattere Scientifico, Policlinico San Matteo, Pavia, Italy

^@ To whom correspondence should be addressed. E-mail: amvannucchi{at}unifi.it.

	Abstract

Acquired mutations in the juxtamembrane region of MPL (W515K or W515L), the receptor for thrombopoietin, have been described in patients with primary myelofibrosis or essential thrombocythemia, which are chronic myeloproliferative disorders. We have developed a real-time polymerase chain reaction assay for the detection and quantification of MPL mutations that is based on locked nucleic acid fluorescent probes. Mutational analysis was performed using DNA from granulocytes. Reference curves were obtained using cloned fragments of MPL containing either the wild-type or mutated sequence; the predicted sensitivity level was at least 0.1% mutant allele in a wild-type background. None of the 60 control subjects presented with a MPLW515L/K mutation. Of 217 patients with myelofibrosis, 19 (8.7%) harbored the MPLW515 mutation, 10 (52.6%) with the W515L allele. In one case, both the W515L and W515K alleles were detected by real-time polymerase chain reaction. By comparing results obtained with conventional sequencing, no erroneous genotype attribution using real-time polymerase chain reaction was found, whereas one patient considered wild type according to sequence analysis actually harbored a low W515L allele burden. This is a simple, sensitive, and cost-effective procedure for large-scale screening of the MPLW515L/K mutation in patients suspected to have a myeloproliferative disorder. It can also provide a quantitative estimate of mutant allele burden that might be useful for both patient prognosis and monitoring response to therapy.

This article has been cited by other articles:

				A. Carobbio, G. Finazzi, E. Antonioli, P. Guglielmelli, A. M. Vannucchi, F. Delaini, V. Guerini, M. Ruggeri, F. Rodeghiero, A. Rambaldi, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia Blood, October 15, 2008; 112(8): 3135 - 3137. [Abstract] [Full Text] [PDF]